Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Anticancer Research

• Publication date

  2015-11-01

• Fields of study

  Medicine

• Identifiers
  PMID 26504040
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prostate cancer risk assessment tools in an unscreened population

  2015cited by this paper
• Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.

  2015cited by this paper
• The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy.

  2015cited by this paper
• Cancer statistics, 2015

  2015cited by this paper
• Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance

  2014cited by this paper
• The feature of metabolic syndrome is a risk factor for biochemical recurrence after radical prostatectomy

  2014cited by this paper
• Corpulence is the crucial factor: Association of testosterone and/or obesity with prostate cancer stage

  2014cited by this paper
• Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men

  2014cited by this paper
• A new era of testosterone and prostate cancer: from physiology to clinical implications.

  2014cited by this paper
• High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients

  2014cited by this paper
• Obesity and prostate cancer: weighing the evidence.

  2013cited by this paper
• Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case–control studies

  2013cited by this paper
• Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: a prospective multicenter Italian cohort study.

  2013cited by this paper
• The role of magnetic resonance imaging in the diagnosis and management of prostate cancer

  2013cited by this paper
• Predicting high risk disease using serum and DNA biomarkers

  2013cited by this paper
• Prostate cancer and metabolic syndrome: is there a link?

  2012cited by this paper
• Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8–10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer

  2012cited by this paper
• Serum Sex Steroids Depict a Nonlinear U-Shaped Association with High-Risk Prostate Cancer at Radical Prostatectomy

  2012cited by this paper
• Body Mass Index, Prostate Cancer–Specific Mortality, and Biochemical Recurrence: a Systematic Review and Meta-analysis

  2011cited by this paper
• Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence

  2011cited by this paper
• Evidence for geographical and racial variation in serum sex steroid levels in older men.

  2010cited by this paper
• The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with meta-analysis.

  2010cited by this paper
• Effect of dutasteride on the risk of prostate cancer.

  2010cited by this paper
• Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients?

  2009cited by this paper
• Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐European study population?

  2009cited by this paper
• Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.

  2009cited by this paper
• Re: Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy.

  2009cited by this paper
• Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels.

  2008cited by this paper
• Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy.

  2008cited by this paper
• Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle‐aged men

  2007cited by this paper
• The association of time of day and serum testosterone concentration in a large screening population

  2007cited by this paper
• Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score.

  2006cited by this paper
• Testosterone as a predictor of pathological stage in clinically localized prostate cancer.

  2005cited by this paper
• The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

  2005cited by this paper
• The influence of finasteride on the development of prostate cancer.

  2003cited by this paper
• High‐grade prostate cancer is associated with low serum testosterone levels

  2001cited by this paper
• Case-control studies of prostate cancer in blacks and whites in southern California.

  1987cited by this paper

• Machine learning discrimination of Gleason scores below GG3 and above GG4 for HSPC patients diagnosis

  2024cites this paper
• Prognostic impact of serum testosterone in metastatic hormone-naive prostate cancer: a systematic review and meta-analysis

  2023cites this paper
• Low serum total testosterone level as a predictor of upgrading in low-risk prostate cancer patients after radical prostatectomy: A systematic review and meta-analysis

  2022cites this paper
• Male hypogonadism with its systemic complications

  2020cites this paper
• Clinical association of metabolic syndrome, C‐reactive protein and testosterone levels with clinically significant prostate cancer

  2018cites this paper
• Smoking effect on oncological outcome among men with prostate cancer after radical prostatectomy

  2017cites this paper
• Central Body Fat Mass Measured by Bioelectrical Impedanciometry But Not Body Mass Index Is a High-Grade Prostate Cancer Risk Factor.

  2017cites this paper
• Central Body Fat Mass Measured by Bioelectrical Impedanciometry But Not Body Mass Index Is a High-Grade Prostate Cancer Risk Factor

  2016cites this paper